INMED ANNOUNCES APPOINTMENT OF WILLIAM J. GARNER, M.D. TO ITS BOARD OF DIRECTORS
– Momentum Public Relations – June 13th, 2016
InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce today the addition of Dr. William J. Garner, M.D., to the Board of Directors. Dr. Garner is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, M&A or IPO transactions. Dr. Garner has extensive director-level and executive management experience, including his current appointment as Chairman & Founder of Update Pharma and as a Director at IGXBio; previously serving as CEO of Invion Limited (ASX:IVX), a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded; and as a co-founder and Director of Del Mar Pharmaceuticals (OCTQX:DMPID). Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche’s oncology division. Prior to Roche, Dr. Garner was a healthcare merchant banker in New York City.
He has a Master of Public Health from Harvard and earned his M.D. at New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York.
“I am excited about joining InMed’s Board,” stated Dr. Garner. “In my review of the drug development programs, which involve topical administration with an inherently reduced risk of systemic toxicity, it became clear that InMed has the potential to achieve important, value-driving milestones in diseases with high unmet medical needs. The ultra-orphan lead indication is a particularly attractive opportunity, in my opinion. Together with the Directors and Management of the Company, I believe my skill sets can augment InMed’s efforts to optimize the development pathway and monetize its many assets.”
InMed also announces it has accepted the resignation of Steve Tong as a Director of the Company, effective today. The Board wishes to thank Mr. Tong for his efforts on behalf of the Company.
About InMed
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics drug candidate identification platform, biosynthesis manufacturing, and accelerated drug development pathway are the fundamental value drivers of the company.